Insulin resistance and cardiovascular disease

Journal of Clinical Investigation

Volumn 106, Issue 4, 2000, Pages 453-458

  Ginsberg, Henry N ^a  

^a Columbia Univ Coll Phys Surgs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; PLASMINOGEN ACTIVATOR INHIBITOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DYSLIPIDEMIA; FATTY ACID METABOLISM; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; INSULIN RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

EID: 0033860359     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI10762     Document Type: Review

References (48)

1. Albrink, M.J., Krauss, R.M., Lindgren, F.T., Von der Groeben, V.D., and Wood, P.D.S. 1980. Intercorrelations among high density lipoproteins, obesity, and triglycerides in a normal population. Lipids. 15:668-678.
2. Reaven, G.M., Lerner, R.L., Stern, M.P., and Farquhar, J.W. 1967. Role of insulin in endogenous hypertriglyceridemia. J. Clin. Invest. 46:1756-1767.
3. Howard, G., et al. 1996. Insulin sensitivity and atherosclerosis. Circulation. 93:1809-1817.
4. Miller, G.J., and Miller, N.E. 1975. Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet. 1:16-19.
5. Welborn, T.A., Breckenridge, A., Rubinstein, A.H., Dollery, C.T., and Fraser, T.R. 1966. Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet. 1:1336-1337.
6. Juhan-Vague, I., Alessi, M., and Vague, P. 1991. Increased plasma PAI-1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 34:457-462.
7. Kahn, B.B., and Flier, J.S. 2000. Obesity and insulin resistance. J. Clin. Invest. 106:473-481.
8. Gavrilova, O., et al. 2000. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J. Clin. Invest. 105:271-278.
9. Klannemark, M., Orho, M., Langin, D.L.H., Holm, C., and Reynisdottir, S. 1998. The putative role of the hormone-sensitive lipase gene in the pathogenesis of Type II diabetes mellitus and abdominal obesity. Diabetologia. 41:1516-1522.
10. Babirak, S.P., Brown, B.G., and Brunzell, J.D. 1992. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler. Thromb. 10:1176-1183.
11. Murray, I., Havel, P.J., Sniderman, A.D., and Cianflone, K. 2000. Reduced body weight, adipose tissue, and leptin levels despite increased energy intake in female mice lacking acylation-stimulating protein. Endocrinology. 141:1041-1049.
12. Wetsel, R.A., Kildsgaard, J., Zsigmond, E., Liao, W., and Chan, L. 1999. Genetic deficiency of acylation stimulating protein (ASP(C3adcs-Arg)) does not cause hyperapobetalipoproteinemia in mice. J. Biol. Chem. 274:19429-19433.
13. Febbraio, M., et al. 1999. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J. Biol. Chem. 274:19055-19062.
14. Ibrahimi, A., et al. 1999. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J. Biol. Chem. 274:26761-26766.
15. Aitman, T.J., et al. 1999. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat. Genet. 21:76-83.
16. Pravenec, M., et al. 1999. Genetics of Cd36 and the clustering of multiple cardiovascular risk factors in spontaneous hypertension. J. Clin. Invest. 103:1651-1657.
17. Gotoda, T., et al. 1999. Absence of Cd36 mutation in the original spontaneously hypertensive rats with insulin resistance. Nat. Genet. 22:226-228.
18. Dixon, J.L., and Ginsberg, H.N. 1993. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J. Lipid Res. 34:167-179.
19. Fisher, E., et al. 1997. Apoprotein B100, an atypical secretory protein, can be degraded by a cytosolic pathway involving heat shock protein 70 and proteasomes. J. Biol. Chem. 272:20427-20434.
20. Lewis, G.F. 1997. Fatty acid regulation of very low density lipoprotein (VLDL) production. Curr. Opin. Lipidol 8:146-153.
21. Lewis, G.F., Uffelman, K.D., Szeto, L.W., and Steiner, G. 1993. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals Diabetes. 42:833-842.
22. Malmstrom, R., et al. 1998. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes. 47:779-787.
23. Malmstrom, R., et al. 1997. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia. 40:454-462.
24. Dammerman, M., Sandkuijl, L.A., Halaas, J.L., Chung, W., and Breslow, J.L. 1993. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc. Natl. Acad. Sci. USA. 90:4562-4566.
25. Bruce, C., Chouinard, R.A., Jr., and Tall, A.R. 1998. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu. Rev. Nutr. 18:297-330.
26. Horowitz, B.S., et al. 1993. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J. Clin. Invest. 91:1743-1752
27. Nordestgaard, B.G., Tybjaerg-Hansen, A., and Lewis, B. 1992. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. Arterioscler. Thromb. 12:6-18.
28. Rapp, J.H., et al. 1994. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler. Thromb. 14:1767-1774.
29. Ginsberg, H.N., et al. 1995. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler. Thromb. Vasc. Biol. 15:1829-1838.
30. Acton, S., et al. 1996. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 271:460-461.
31. Arai, T., Wang, N., Bezouevski, M., Welch, C., and Tall, A.R. 2000. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J. Biol. Chem. 274:2366-2371.
32. Sniderman, A.D., et al. 1982. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann. Intern. Med. 97:833-839.
33. Austin, M.A., King, M.D., Vranizan, K.M., and Krauss, R.M. 1990. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 82:495-506.
34. Bonora, E., et al. 1998. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 47:1643-1649.
35. Laakso, M., Edelman, S.V., Brechtel, G., and Baron, A.D. 1990. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J. Clin. Invest. 85:1844-1852.
36. Steinberg, H.O., et al. 1997. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J. Clin. Invest. 100:1230-1239.
37. Yusuf, S., et al. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med 342:145-153.
38. Defronzo, R.A., Cooke, C.R., Andres, R., Faloona, G.R., and Davis, P.J. 1975. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J. Clin. Invest. 55:845-855.
39. Landsberg, L. 1999. Insulin resistance and hypertension. Clin. Exp. Hypertens. 21:885-894.
40. Miller, G.J. 1995. Lipoproteins and thrombosis: effects of lipid lowering. Curr. Opin. Lipidol. 6:38-42.
41. Hamsten, A., Wiman, B., de Faire, U., and Blomback, M. 1985. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N. Engl. J. Med. 313:1557-1563.
42. Eriksson, P., Nilsson, L., Karpe, F., and Hamsten, A. 1998. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 18:20-26.
43. Calles-Escandon, J., Mirza, S.A., Sobel, B.E., and Schneider, D.J. 1998. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes. 47:290-293.
44. Li. X.N., et al. 1997. Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 17:3215-3223.
45. Law, R.E., et al. 1996. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J. Clin. Invest. 98:1897-1905.
46. Marx, N., Schonbeck, U., Lazar, M.A., Libby, P., and Plutzky, J. 1998. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 83:1097-1103.
47. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 352:837-853.
48. Nordestgaard, B.G., Agerholm-Larson, B., and Stender, S. 1997. Effect of exogenous hyperinsulinaemia on atherogenesis in cholesterol-fed rabbits. Diabetologia. 40:512-520.